NVIDIA Infrastructure Powers Mayo Clinic’s Digital Pathology AI Efforts

Earlier this year a company called Aignostics published research results for a new pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. 

Aignostics said that the model, called Atlas, was built in two months using 1.2 million diverse slide images from Mayo Clinic and Charité – Universitätsmedizin Berlin. The company said the model “establishes a new state-of-the-art for performance across more than 20 public benchmarks. In addition, the model is computationally efficient, enhancing its usability relative to existing image-based models. With Atlas, Mayo Clinic said, clinicians and researchers can improve accuracy and reduce administrative tasks. 

Now Mayo Clinic is highlighting its deployment of NVIDIA DGX SuperPOD with NVIDIA DGX B200 systems, an infrastructure that Mayo Clinic says provides state-of-the-art AI compute capabilities to support digital pathology and other areas of development.

Mayo Clinic Digital Pathology is working to advance areas such as scanning, storage, foundation model development and the creation and deployment of cutting-edge algorithms. Wholly owned by Mayo Clinic, Mayo Clinic Digital Pathology seeks to incubate and start impactful companies while investing in and acquiring existing companies.

The advanced computing infrastructure will initially support foundation model development for pathomics, drug discovery and precision medicine.

The NVIDIA Blackwell-powered DGX SuperPOD is built to process large, high-resolution imaging essential for AI foundation model training. 

The Blackwell infrastructure enables Mayo Clinic to accelerate pathology slide analysis and foundation model development — reducing four weeks of work to just one, according to Mayo Clinic. This advanced computing infrastructure will also advance Mayo Clinic’s generative AI and multimodal digital pathology foundation model development.

"This compute power, coupled with Mayo’s unparalleled clinical expertise and platform data of over 20 million digitized pathology slides, will allow Mayo to build on its existing foundation models,” said Jim Rogers, CEO of Mayo Clinic Digital Pathology, in a statement. “We’re transforming healthcare by quickly and safely developing innovative AI solutions that can improve patient outcomes and enable clinicians to dedicate more time to patient care while also accelerating commercial affiliations with other industry leaders.”

"Our aspiration for AI is to meaningfully improve patient outcomes by detecting disease early enough to intervene. What was once a hypothetical — 'If only we had the right data' — is now becoming reality thanks to AI and advanced computing," says Matthew Callstrom, M.D., Ph.D., medical director of the Department of Strategy and leader of Mayo Clinic’s Generative Artificial Intelligence Program, in a statement.